Vectus Biosystems Limited
AASX:VBS0.09
AUD
-0.01
(-14.29%)
ISIN
AU000000VBS9
Return %
Stock
S&P 500
1Y
21.62
14.20
3Y
-75.00
81.12
5Y
-95.26
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Tara Speranza
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 26-34 Dunning Avenue Rosebery NSW Australia 2018
- IPO Date
- Feb 22, 2016
- Website
- vectusbiosystems.com.au
- Similar Companies
- Business
- Vectus Biosystems Limited is an Australian biotechnology company engaged in the discovery and development of therapeutic treatments primarily targeting fibrosis and hypertension. The company’s core products include its lead drug candidate VB0004, which is designed to treat fibrosis and high blood pressure associated with major fibrotic diseases affecting the heart, liver, and kidneys. In addition to drug development, Vectus offers pre-clinical toxicity testing services utilizing animal and human cell models and has developed proprietary technology through its wholly-owned subsidiary Accugen Pty Limited, which enhances the speed and accuracy of DNA and RNA quantification in laboratory samples. Founded in 2011 and headquartered in Rosebery, New South Wales, Vectus Biosystems focuses its operations predominantly in Australia with research activities aligned to unmet medical needs in cardiovascular and fibrotic diseases. Recent major developments include the progression of VB0004 through various clinical trial phases, notably the completion of a phase 1a trial showing a strong safety profile, and advancement into phase 1b to further evaluate efficacy and safety. The company has raised capital through share placements and convertible note fundraising to support these clinical trials. Additionally, Vectus is advancing the commercialisation of its Accugen technology through potential direct sales, distribution partnerships, and licensing arrangements. These activities represent significant operational progress within the last two years, aimed at accelerating drug development and expanding its technology platform in the biotech sector. Vectus Biosystems remains publicly listed on the Australian Securities Exchange under the ticker VBS, continuing its strategic focus on pharmaceutical innovation and diagnostic technology development.